Its really sad we dont see more publication about telomerase therapy. Its really promising…
did the csv telomerase therapy from bioviva finally treat some people ?
This is new. Triple gene therapy now available at 20% the price that Bioviva was offering. Ie $75k now, for follistatin, klotho, and Sirt-1. AAV vector. They claim it will last 15 - 20 years. I think you have to be over 50 or they won’t take you.
I wish they had included hTert 
4 Likes
I’m always a little concerned with the AAV vector. It can integrate anywhere… so could potentially disrupt another gene. I wonder what the precise risk of “off-target” effects are?
1 Like
Agreed. Personally I’ll wait for better and safer vectors. I hope Bioviva gets CMV working soon.
Meanwhile there’s a GMP injectable klotho available that I might try.
2 Likes
Your concern is valid, but recombinant AAVs mostly remain episomal… low-frequency integration can occur, yet no clear case of AAV-mediated insertional oncogenesis has been documented in humans to date, so the real safety focus should be dose, tissue targeting, immune toxicity and long-term monitoring.
Integrated Health System seems to perform it since a long time. Not sure if its legit yet ?
A study from 2021 : https://www.researchgate.net/publication/356068464_Safety_Study_of_AAV_hTert_and_Klotho_Gene_Transfer_Therapy_for_Dementia
1 Like